Xenon Pharmaceuticals Inc.
XENE
$40.15
$1.092.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.50M | 7.50M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.50M | 7.50M | -- | -- | -- |
| Cost of Revenue | 252.63M | 227.34M | 210.39M | 192.00M | 177.91M |
| Gross Profit | -245.13M | -219.84M | -210.39M | -192.00M | -177.91M |
| SG&A Expenses | 72.99M | 73.15M | 68.90M | 63.52M | 59.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 325.62M | 300.50M | 279.30M | 255.52M | 237.52M |
| Operating Income | -318.12M | -293.00M | -279.30M | -255.52M | -237.52M |
| Income Before Tax | -282.60M | -255.52M | -238.42M | -213.83M | -199.34M |
| Income Tax Expenses | -4.37M | -4.07M | -4.09M | -446.00K | -283.00K |
| Earnings from Continuing Operations | -278.23 | -251.45 | -234.33 | -213.39 | -199.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -278.23M | -251.45M | -234.33M | -213.39M | -199.06M |
| EBIT | -318.12M | -293.00M | -279.30M | -255.52M | -237.52M |
| EBITDA | -315.53M | -290.39M | -276.77M | -252.77M | -233.71M |
| EPS Basic | -3.54 | -3.22 | -3.01 | -2.81 | -2.74 |
| Normalized Basic EPS | -2.25 | -2.04 | -1.91 | -1.76 | -1.72 |
| EPS Diluted | -3.54 | -3.22 | -3.01 | -2.81 | -2.74 |
| Normalized Diluted EPS | -2.25 | -2.04 | -1.91 | -1.76 | -1.72 |
| Average Basic Shares Outstanding | 313.95M | 312.67M | 311.58M | 303.16M | 291.24M |
| Average Diluted Shares Outstanding | 313.95M | 312.67M | 311.58M | 303.16M | 291.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |